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Abstract
Background: There is a dearth of data regarding the optimal method of detecting and treating depression in
palliative care. This study applied the Delphi method to evaluate expert opinion on choice of screening tool,
choice of antidepressant and choice of psychological therapy. The aim was to inform the development of best
practice recommendations for the European Palliative Care Research Collaborative clinical practice guideline on
managing depression in palliative care.
Methods: 18 members of an international, multi-professional expert group completed a structured questionnaire in
two rounds, rating their agreement with proposed items on a scale from 0-10 and annotating with additional
comments. The median and range were calculated to give a statistical average of the experts’ ratings.
Results: There was contention regarding the benefits of screening, with ‘routine informal asking’ (median 8.5 (0-
10)) rated more highly than formal screening tools such as the Hospital Anxiety and Depression Scale (median 7.0
(1-10). Mirtazapine (median 9 (7-10) and citalopram (median 9 (5-10) were the considered the best choice of
antidepressant and cognitive behavioural therapy (median 9.0 (3-10) the best choice of psychological therapy.
Conclusions: The range of expert ratings was broad, indicating discordance in the views of experts. Direct
comparative data from randomised controlled trials are needed to strengthen the evidence-base and achieve
clarity on how best to detect and treat depression in this setting.
Background
The management of depression in palliative care is com-
plicated by the physical and psychosocial effects of
advanced disease. The somatic symptoms of depression
(e.g. fatigue, insomnia and poor appetite) mimic those
of advanced illness, making it difficult to determine
whether such symptoms are due to depression or physi-
cal disease [1]. Moreover, in palliative care it is difficult
to differentiate depression from understandable fear and
distress relating to declining health and impending
death [2]. Antidepressant drugs and psychological thera-
pies are the most common treatments for depression,
yet there is limited evidence for their efficacy in pallia-
tive populations [3-5]. Further, studies suggest that in
palliative care depression frequently goes untreated [6],
and that interventions are often initiated so late that
patients die before they have time to take effect [7].
The European Palliative Care Research Collaborative
(EPCRC) recently produced a clinical guideline for the
management of depression in palliative care to improve
care for this population [8]. The purpose of the guide-
line is to provide recommendations on preventing,
detecting and treating depression in palliative care, in
order to aid decision-making, establish clinical policy
and improve patient outcomes. Recommendations were
devised using the best available evidence. Where evi-
dence was equivocal or absent, expert opinion was
sought. At the beginning of the project, an expert group
was constituted to identify clinical priorities and offer
knowledge, experience and opinion on contentious
aspects of clinical practice. Literature scoping and initial
discussions with the expert group revealed two main
areas of uncertainty:
1) Choice of screening tool
Detection of depression in palliative care is bedevilled by
ap l e t h o r ao ft o o l sa n dap a u c i t yo fe v i d e n c e[ 9 ] .
Though few studies have shown screening to impact
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as a simple, systematic and cost-effective way of improv-
ing identification of depression in medical settings [11].
To be useful to clinicians, screening tools must balance
validity of assessment against brevity. Many tools were
developed for use in physically healthy people and their
applicability to palliative carei sq u e s t i o n a b l e[ 1 2 ] .T h e
multitude of screening tools used in clinical practice
and research attests to the current confusion surround-
ing the optimal method of detecting depression in pal-
liative care [13].
2) Choice of treatment
Screening should always be complemented by effective
treatment and a comprehensive management strategy
[14,15]. Antidepressants have been shown to be effica-
cious and acceptable for treating depression in patients
with life-threatening illness [16]. However, there is
insufficient direct comparative data to recommend one
antidepressant over others. Choosing an antidepressant
for palliative care patients with multiple symptoms and
medications is particularly challenging because of the
increased risk of drug interactions and contraindications.
Psychological therapy is the other recommended treat-
ment for depression [11], but there are questions sur-
rounding its feasibility and acceptability in palliative
care. A recent Cochrane review found that psychother-
apy was effective in treating depressive states in patients
with advanced cancer [5]. However, there were not
enough trials to draw conclusions regarding the relative
efficacy of different types of therapy.
As there was insufficient evidence in the literature to
guide choice of screening tool and choice of treatment,
we conducted a Delphi study to evaluate expert opinion
and inform the EPCRC guideline recommendations.
The following research questions were posed:
1) Which screening tool is most useful for detecting
depression in palliative care?
2) Which antidepressant is most appropriate for treat-
ing depression in palliative care?
3) Which psychological therapy is most appropriate
for treating depression in palliative care?
Method
Design
We used the Delphi method to assess expert opinion on
screening for and treating depression in palliative care.
Delphi is a formal consensus technique used to obtain
and evaluate the views of an expert group with knowl-
edge and experience in a specialised area. It has been
found to be an effective method for determining the
level of expert consensus on clinical questions and it is
increasingly used in research [17]. Correspondence is
carried out by email, making Delphi a feasible method
for achieving consensus in a multinational expert group.
M o r e o v e r ,t h i sa l l o w sa n o n y m i t ya n dp r e v e n t sp r o m i -
nent members of the group from exerting undue influ-
ence. Delphi is an iterative process involving repeated
expert input and statistical description of responses. The
aim is to elicit experts’ views and encourage converging
opinion on uncertain or contentious issues.
Participants
An expert group was constituted to evaluate the per-
spectives and priorities of professionals with knowledge
and experience in managing depression in palliative
care. Expert nominations were sought via the European
Association of Palliative Care (EAPC) board, the EAPC
website and other palliative care associations in Europe.
Experts were selected by the EPCRC guideline steering
group based on their clinical expertise and research
experience. To capture social, cultural and disciplinary
differences, the Expert Group comprised 29 profes-
sionals from a range of disciplines and different coun-
tries (see Table 1).
Procedure
Items relating to choice of screening tool, choice of anti-
depressant and choice of psychological therapy were
included in a structured questionnaire (see Additional
file 1). These topics were chosen in consultation with
t h eE x p e r tG r o u p .Al i s to fk e yc l i n i c a lq u e s t i o n sw a s
drafted by the EPCRC guideline development group
(LR, MH, AP, IHJJ) based on the existing literature and
emailed to the Expert Group who commented on its
scope and relevance. The list was refined and experts
were asked to rate the clinical importance of included
items. The questions included in the Delphi question-
naire were those rated most highly by the expert group.
The Delphi method was applied in two rounds. In the
first round, the questionnaire was emailed to the expert
group with a request for members to rate their level of
agreement with each item on a scale from 0 to 10. The
experts were invited to leave comments to annotate their
ratings and to suggest additional items to be included in
the second round. In the second round the median and
range of ratings were reported to the group together with
anonymised comments. Items suggested by experts in the
first round were added to the Delphi questionnaire,
which the expert group was requested to complete again
in light of the results of the first round. The median and
range reported below are from the second round of Del-
phi as this represents the final view of the expert group.
Results
Eighteen of the 29 experts (62%) returned a question-
naire in one or both rounds of the Delphi exercise.
Respondents included seven palliative care physicians,
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tive care), two psycho-oncologists, a behavioural psy-
chotherapist, a clinical psychologist and a general
practitioner.
Screening
After the second round of Delphi, the Hospital Anxiety
and Depression Scale (HADS) (median 7.0, range 2-9)
[18], the single question “Are you depressed? (median
7.0, range (0-10) [19] and two questions assessing low
mood and low interest (median 7.0, range 1-10) [20]
were rated as the most useful screening tools for detect-
ing depression in palliative care (see Table 2). However,
the experts’ comments indicate some concern about the
specificity of such screening tools: “It does sort of work,
but pretty non-discriminating"; “Not really specific”.
Screening for depression using a generic symptom
assessment tool (such as the Palliative Outcome Scale
(POS) [21-23]) was also considered a useful method of
detection by the expert group (median 6.5, range 1-10):
“...utilizes open questions within a conversation about
many other symptoms, hence less fear, less defence in
answer...”. Interestingly, the item “Routine informal ask-
ing” (suggested by an expert in the first round and
included in the second iteration of the questionnaire)
was rated more highly than any of the formal screening
tools in the second round of Delphi (median 8.5, range
0-10). The Brief Edinburgh Depression Scale (BEDS),
the Prime-MD PHQ-9, the Beck Depression Inventory
(BDI) and the Distress Thermometer each achieved a
median rating of 5.0 or lower. The experts’ comments
indicate that the Prime-MD PHQ-9 and the Beck
D e p r e s s i o nI n v e n t o r y( B D I )m a yb em o r es u i t a b l ef o r
assessing the severity of depression than for screening:
“After screening, if practitioner is experienced and confi-
dent to use, but this is really for specialist psychiatric
services"; “For assessment"; “It’s a severity tool...”.
Antidepressant treatment
Mirtazapine (median 9.0, range 7-10) and citalopram
(median 9.0, range 5-10) were considered the best choice
of antidepressant for treating depression in palliative care
(see Table 3). Venlafaxine (median 8.0, range 0-9), sertra-
line (median 7.5, range 0-10) and escitalopram (median
7.0, range 0-10) were also rated as useful by the expert
group. Of all the drugs, the range of ratings was smallest
for mirtazapine (7-10), indicating expert agreement
regarding its advantages for this patient group. This was
reflected in the additional comments about mirtazapine:
“M yf i r s t - l i n e-e v i d e n c ei st h a ti ti sm o r ee f f e c t i v et h a n
SSRIs and appetite stimulant and sedative qualities are
useful side effects"; “...good profile regarding side effects,
at this time most used”.
Though no TCA scored highly in the Delphi study,
amitriptyline achieved the highest median score (median
5.0, range (1-9) probably on account of its efficacy in
alleviating neuropathic pain:; “...clinically I would favour
those drugs that are used most often in palliative care
anyway e.g. amitriptyline"; “If indicated for neuropathic
pain”. The least favoured SSRIs were fluoxetine (median
3.0, range 0-6): “Too long half-life, not useful for physi-
cally ill people”, and paroxetine (median 5.5, range 0-9):
“Interactions and withdrawal problems”.O fa l lt h ea n t i -
depressants, mianserin was rated most poorly: “No point
really - it is pharmacologically similar to mirtazapine,
which doesn’t hit the white blood cells”.
Psychological therapy
Cognitive behavioural therapy was the experts’ preferred
choice of psychological therapy (median 9.0, range 3-
Table 1 Background of the expert group
n =2 9
Profession
Clinical psychologist 2
Psychiatrist 10
Physician 12
Psychotherapist 1
Nurse 1
Chaplain 1
Social worker 1
Pharmacist 1
Present work setting
Clinical practice in palliative care 15
Research in palliative care 12
Psycho-oncology 1
Liaison psychiatry 1
CBT in physical illness 3
Social work 1
Oncology 4
Old age psychiatry 1
Pharmacy 1
Gender
Female 13
Male 16
Country
Canada 1
US 2
UK 16
Austria 1
Italy 3
Norway 1
The Netherlands 1
Spain 1
France 2
Germany 1
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range 3-10) (see Table 4). The item “Presence of a spiri-
tual assistant upon request” was suggested by an expert
in the first round and then achieved the third highest
rating in the second round (median 7.5, range 1-10).
Comments included: “We have to get better at specifi-
cally enquiring about the presence of a spiritual dimen-
sion to distress"; “Not for all patients - just on request”.
Mindfulness-based therapy, guided imagery and narra-
tive therapy each achieved a median rating of 7.0.
Overall, fewer experts responded to the psychological
therapy question, possibly on account of the expert
group including fewer psychologists than psychiatrists.
The lower response to this question may also indicate
difficulty rating items in the absence of evidence:
“Although psychotherapy at the end of life has some
evidence base, there is less evidence for the effectiveness
of individual therapies, so I feel unable to rate”.
Discussion
Screening
A single question assessing depression [19] and two
questions assessing low mood and loss of interest [20]
were rated as moderately useful by the expert group
Table 2 Experts’ ratings: Method of detection
Method
0 = not useful, 10 = very useful
Experts’ comments
Routine informal asking*
Round 2: Median 8.5 (0-10); n = 10
-It is entirely appropriate to ask patients about their mood as part of a comprehensive symptom
assessment
Two-items (low mood & loss of
interest)
Round 1: Median 8.0 (4-10); n = 13
Round 2: Median 7.0 (2-9); n = 13
-Too rigid, it seems the shortest summary of a long screening questionnaire
-There is evidence to support this
-We are talking about screening, not assessment: if patient presents with a symptom then full
assessment, but if screening otherwise mentally well population then this is a useful tool
Hospital Anxiety and Depression Scale
Round 1: Median 7.0 (1-10); n = 13
Round 2: Median 7.0 (1-10); n = 13
-Long to complete for palliative care patients
-Have used it in palliative care patients very successfully
-I don’t find this difficult to use in palliative care in hospice or hospital setting, even for pretty weary
patients
-Is just a screener for emotional distress, not useful in diagnosing depression
-Very useful, very acceptable, very under-rated. For some reason the palliative care community have got
it in for the HADS, but I don’t think there is any evidence that any other measure is better, and quite a
few are a lot worse
-Less clear distinction between depression and anxiety
Single-item “Are you depressed?”
Round 1: Median 5.0 (0-10); n = 13
Round 2: Median 7.0 (0-10); n = 12
-I know the limitations, but in my experience helpful in daily practice
-Not really specific
-Too direct and one closed question is not enough screening
-Chochinov’s first paper was based on a false premise. It does sort of work, though, but pretty non-
discriminating
As part of generic symptom
assessment (e.g. POS, ESAS)
Round 1: Median 7.0 (2-10); n = 13
Round 2: Median 6.5 (1-10); n = 14
-Good just as first wide screening, utilizes open questions within a conversation about many other
symptoms, hence less fear ... less defence in answer, nevertheless not enough for a full screening
-These aren’t at all bad
-Screening by definition has to be simple and quick. Don’t confuse screening with severity assessment,
there needs to be a 2 stage process: 1) screen; 2) if patient screens positive then use a tool to assess
severity
Brief Edinburgh Depression Scale
(BEDS)
Round 1: Median 8.0 (2-10); n = 9
Round 2: Median 5.0 (1-9); n = 12
-Easy to use
-The simplified version; but the 6 sentences are too crude for our patients
Beck’s Depression Inventory*
Round 2: Median 5.0 (0-8); n = 12
-Largely about thinking style and content and thus relatively un-skewed by physical problems. A better
scale for measuring progress than HADS
-Better use only for assessment
-After screening, if practitioner is experienced and confident to use, but this is really for specialist
psychiatric services
Prime-MD PHQ-9
Round 1: Median 5.0 (0-10); n = 11
Round 2: Median 3.0 (0-9); n = 11
-Too complex
-Too long
-For assessment
-It’s a diagnostic tool, but it’s pretty acceptable and not very difficult to use
-I t ’s a severity tool, it is easy to use, primary care practitioners will be familiar with this
Distress Thermometer (DT)
Round 1: Median 6.0 (0-8); n = 9
Round 2: Median 2.0 (0-10); n = 13
-Distress and depression are different
-Useful screen for generalists to decide whether to refer for specialist help
-Useful to integrate depression in routine screening of other symptoms, mixed with distress, hence
perceived by patients not as psychiatric inquiry.
*Items suggested by experts in the first round and rated by the group in the second round
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these items are effective at excluding depression in the
non-depressed, they are less successful at confirming
cases [24], and this was reflected in the experts’ com-
ments. Nevertheless, some clinicians valued these ‘ultra-
short’ screening tools: “I know the limitations, but in my
experience helpful in daily practice”.O ft h el o n g e r
screening tools, the HADS was rated most highly (med-
ian 7). Though one expert felt that the HADS was too
long for palliative patients, a number commented that
they had used it successfully in this setting.
Our initial objective was to determine the optimal
screening tool for detecting depression in palliative care,
yet perhaps the most important finding was that the
experts rated ‘informal routine asking’ as more useful
than administering a specified screening tool. Clinicians
and patients may feel more relaxed and open if mood is
considered in the context of a general conversation
about symptoms, coping and well-being. This ‘holistic’
approach allows patients to tell their story and empha-
sise the issues important to them [25]. It is possible that
am o r er i g i d‘tick-box’ approach may detract from dee-
per engagement with patients’ problems.
Screening for depression has been recommended by
several influential bodies [11,26]. However, research on
screening has focused on tool development and valida-
tion [27,28], and the less easily evaluated yet fundamen-
tal question of whether screening improves patient
outcomes remains unanswered [29]. We know of no
randomised controlled trials assessing the impact of
Table 3 Experts’ ratings: Choice of antidepressant
Drug
0 = not useful, 10 = very useful
Experts comments
Mirtazapine
Round 1: Median 9.0 (7-10); n = 11
Round 2: Median 9.0 (7-10); n = 11
-Some data, good profile regarding side effects, at this time most used
-Seems well tolerated
-When side effects on sleep and appetite are handy
-Too soft
-Has useful sedative properties and well tolerated
-My first-line - evidence is that it is more effective than SSRIs and appetite stimulant and sedative qualities are
useful side effects
Citalopram
Round 1: Median 9.0 (5-10); n = 11
Round 2: Median 9.0 (5-10); n = 13
-Side effects due to its antIHJJistaminic action
Venlafaxine
Round 1: Median 7.5 (0-10); n = 8
Round 2: Median 8.0 (0-9); n = 13
-Less side effects than tricyclics
-Useful if patient needs help for sedation
-If depression is associated with chronic high level of anxiety
-Not straightforward - discontinuation symptoms common. Cardiac toxicity
Sertraline
Round 1: Median 7.0 (2-10); n = 11
Round 2: Median 7.5 (0-10); n = 12
-Favourable side effect profile
-Interaction with dopamine system could give different and more side effects than other SSRIs
-Least adverse effects, presently best available
Escitalopram
Round 1: Median 8.0 (0-10); n = 10
Round 2: Median 7.0 (0-10); n = 13
-Not cost effective alternative to citalopram
-Better tolerated than R-citalopram and less interaction with cytocrome 450 2D6
Amitriptyline
Round 1: Median 5.0 (1-9); n = 10
Round 2: Median 4.0 (0-8); n = 12
-Side-effects
-Too sedative, effect too delayed, frequent compliance obstacle due to side effects
-If indicated for neuropathic pain
-For individual TCAs I don’t think there is sufficient evidence to differentially rate, although clinically I would
favour those drugs that are used most often in palliative care anyway e.g. amitriptyline
-An excellent antidepressant
Paroxetine
Round 1: Median 5.5 (0-9); n = 10
Round 2: Median 3.0 (0-7); n = 13
-Too many pharmacological interactions
-Interactions and withdrawal problems
-No place - withdrawal syndrome
Fluoxetine
Round 1: Median 3.0 (0-6); n = 10
Round 2: Median 3.0 (0-6); n = 13
-Too long half time, not useful for physically ill people
-Long t1/2 and interactions
-Too disinhibitory, but not better antidepressant than other SSRIs
Imipramine
Round 1: Median 5.0 (0-6); n = 7
Round 2: Median 2.0 (0-8); n = 11
-Just in patients with depressive history who have already utilized before
Nortriptyline
Round 1: Median 2.0 (0-9); n = 9
Round 2: Median 2.0 (0-7); n = 11
-If indicated for neuropathic pain
-Less than amitriptyline
Mianserin
Round 1: Median 5.0 (0-9); n = 7
Round 2: Median 0.0 (0-7); n = 11
-Little used in practice compared with other drugs and little evidence available
-No point really - it is pharmacologically similar to mirtazapine, which doesn’t hit the white cells
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suggest that its effects would be different from that
found in other patient groups. A meta-analysis by Gil-
body et al showed that introduction of depression
screening in non-mental health settings was associated
with a modest increase in the detection of depression
(RR 1.27 (CI 1.02-1.59)), but had no effect on depression
outcomes (Standardised mean difference -0.02 (CI -0.25-
0.20)) [10]. However, this review only included studies
that evaluated screening alone without further enhance-
ment of care (e.g. case managers, nursing interventions,
collaborative care). Identifying distress is just one link in
a chain of actions needed to optimally manage depres-
sion. Improving patient outcomes requires a compre-
hensive system of care that addresses each link:
detection, diagnosis, assessment, appropriate referral and
effective intervention. Whilst screening for depression is
useful as a catalyst to consider subsequent action, its
intrinsic value is unclear. We assessed experts’ preferred
methods of detecting and treating depression in pallia-
tive care, but we did not address the decisions and
actions required after detection to instigate appropriate
and effective intervention. Future studies would benefit
from a qualitative component exploring if and how
positive screening outcomes influence treatment deci-
sions and patient care. Further, data on the proportion
of potential cases followed up with a diagnostic inter-
view could elucidate the apparent gap between screening
and subsequent benefit for the patient.
Antidepressant treatment
Of the eleven antidepressants rated by the expert group,
five achieved a median rating of 7 or higher, whilst six
were rated 4 or lower. This shows a clear distinction
between the antidepressants considered to be a good
choice for treating depression in palliative care (mirtaza-
pine, citalopram, venlafaxine, sertraline, escitalopram),
and those considered less appropriate (amitriptyline,
paroxetine, fluoxetine, imipramine, nortriptyline, mian-
serin). Whilst there was some consensus about choice of
antidepressant, this should not be mistaken for clear evi-
dence that one treatment is more effective than others.
Such evidence can only be achieved from a randomised
controlled trial, and evidence from the Delphi exercise
is by comparison weak. However, with the exception of
citalopram, the antidepressants rated highly by the
expert group matched those found to be most effica-
cious in Cipriani’s recent meta-analysis comparing 12
Table 4 Experts’ ratings: Choice of psychological therapy
Therapy
0 = not useful, 10 = very useful
Experts comments
Cognitive Behavioural Therapy (CBT)
Round 1: Median 9.5 (4-10); n = 12
Round 2: Median 9.0 (3-10); n = 12
-Choice depends on therapist’s expertise and patient’s preference!!
-Although psychotherapy at the end of life has some evidence base, there is less evidence for the
effectiveness of individual therapies, so I feel unable to rate.
-Is there any evidence anywhere that any of the below are effective interventions, and do no harm. Too
much unproven ‘counselling’ has caused harm over decades that I would not want my patients and their
carers exposed to this
Problem-solving Therapy
Round 1: Median 10.0 (1-10); n = 11
Round 2: Median 8.0 (3-10); n = 12
-Probably better chance than CBT
-Too superficial
Presence of spiritual assistant upon
request*
Round 2: Median 7.5 (1-10); n = 9
-We have to get better at specifically enquiring about the presence of a spiritual dimension to distress
-Not for all patients - just on request
Mindfulness-based therapy
Round 1: Median 7.0 (0-10); n = 9
Round 2: Median 7.0 (0-10); n = 10
-Useful for those who can learn it: interestingly, ‘living in the moment’ is a strategy spontaneously
adopted by many patients who are coping well under difficult circumstances
-Not sure if there’s any evidence
Guided imagery
Round 1: Median 6.0 (1-10); n = 11
Round 2: Median 7.0 (3-9); n = 9
-Temporarily relieves symptoms - but empowering and engenders hope
-Sometimes impossible for cultural or age resistance
Narrative Therapy
Round 1: Median 5.0 (0-8); n = 9
Round 2: Median 7.0 (0-9); n = 9
-I have experience: running well, easily accepted - especially by aged people - empowers the patient and
increases his/her communication with loved ones
-Not sure if there’s any evidence
Music Therapy*
Round 2: Median 6.0 (0-8); n = 9
-For those who cannot be reached by words
-More evidence for relief of physical symptoms than depression
Interpersonal Therapy
Round 1: Median 5.5 (0-10); n = 10
Round 2: Median 5.0 (0-8); n = 10
-Probably too time-consuming
Couple therapy
Round 1: Median 5.0 (1-8); n = 12
Round 2: Median 4.0 (0-8); n = 11
-Can be very useful
-Useful just if the family is reduced to two relevant people
*Items suggested by experts in the first round and rated by the group in the second round
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tified as most efficacious in this meta-analysis, sertraline
and escitalopram were better tolerated than mirtazapine
and venlafaxine [30]. The extent to which Cipriani’s
findings from trials in physically well people can be
extrapolated to patients receiving palliative care is open
to debate. In palliative care, the coexistence and interac-
tion of multiple symptoms and treatments complicates
choice of antidepressant. The side effects of specific
antidepressants may alleviate or exacerbate different
symptoms of advanced disease. For example, tricyclic
antidepressants can relieve neuropathic pain [31], but
are generally contraindicated for patients with heart dis-
ease or liver failure [32]. The side effects of mirtazapine
include sedation and weight gain [33], which are unde-
sirable for most physically well people, but benefit many
palliative care patients, particularly those with loss of
appetite, a major concern for many patients and their
families.
In addition to the present Delphi study, the authors
have conducted a meta-analysis of antidepressants for
depression in physical illness [4] and reported a more
detailed analysis of those studies which examined
depression in life-threatening illness [16]. Our review
showed that antidepressants were more effective than
placebo in treating depression in this context. There
were not enough trials to enable us to assess the efficacy
and acceptability of specific antidepressants, but we did
conduct a subgroup analysis comparing classes of anti-
depressant. All the studies compared individual antide-
pressants with placebo and did not make direct
comparisons between different antidepressants, therefore
it is difficult to draw conclusions on the relative toler-
ability and effectiveness of classes of antidepressants,
Nevertheless, indirect comparison suggested that in
these populations there were no obvious differences
between SSRIs and tricyclics in terms of drop out from
treatment, and the TCAs were possibly more effective.
The combined effect size for the three trials using mian-
serin or mirtazapine exceeded that observed for both
SSRIs and TCAs. This gives some indirect credence to
the expert group’s high rating of mirtazapine, though
comparative trials are needed before conclusions can be
drawn.
Psychological therapy
In line with current NICE guidance [11,34], the expert
group rated CBT as the most useful psychological ther-
apy for depression in palliative care. Though there is
good evidence for CBT in people without physical ill-
ness, there is a paucity of data in palliative care [35,36].
A systematic review by Coventry et al identified two
RCTs showing CBT to reduce depressive symptoms in
COPD patients [35], and a recent cluster randomised
trial showed that training palliative care nurses in CBT
reduced patients’ anxiety, but no significant effect was
found for depression [37]. For problem-solving therapy
studies are scarcer still, though its simplicity and brevity
make it a popular choice in palliative care - as reflected
in the experts’ ratings. The item “Presence of spiritual
assistant upon request” was suggested by an expert in
the first round of Delphi, and then attained the third
highest rating in the second round. Life-threatening ill-
ness poses existential challenges that can exacerbate dis-
tress at the end of life and surveys have indicated that
around one third of cancer patients have unmet spiritual
needs [38,39]. The expert group’s endorsement of spiri-
tual assistance as a useful intervention in palliative care
is corroborated by a recent survey showing an associa-
tion between spiritual care and better quality life near
death [40]. However, the efficacy of spiritual care in spe-
cifically improving depression outcomes has not been
determined, and nor is it likely that such an approach
will be testable in a conventional RCT. Rather than see
spiritual care as competing with conventional psy-
chotherapies, it might be better conceptualised as an
adjunct for those patients who wish to have it. Mindful-
ness-based therapy, guided imagery and narrative ther-
apy were rated as moderately useful by the expert group
(median 7) despite a lack of evidence in palliative care.
Randomised controlled trials of these therapies are
needed to provide an evidence base to support expert
opinion.
Strengths and limitations
Although modest, our 62% response rate is similar to
that achieved in previous studies in which the Delphi
method has been applied in palliative care research
[17,41]. Several reminder emails were sent to the expert
group as a whole, but we felt that pursuing non-respon-
ders individually would detract from the anonymity of
the Delphi process.
The multinational nature of the expert group enabled
the Delphi study to capture the views of experts from
ten European countries. However, development of the
guideline was led by a UK research group and there was
a British bias in the composition of the expert group. As
a consequence our findings may be more representative
of the views of UK health care professionals, and less
applicable to other European countries. The expert
group was multidisciplinary to encompass the perspec-
tives of the different professions involved in the manage-
ment of depression in palliative care. Despite this, we
acknowledge that certain disciplines, such as psychology
and nursing may have been under-represented [42].
Previous studies have demonstrated the potential for
the Delphi process to increase expert consensus (indi-
cated by a reduction in the range of ratings from
Rayner et al. BMC Palliative Care 2011, 10:10
http://www.biomedcentral.com/1472-684X/10/10
Page 7 of 9round to round). In this study the spread of expert
responses tended to remain broad in both rounds,
indicating entrenched differences in palliative care pro-
viders’ views on how best to detect and treat depres-
sion. However, experts’ ratings of the appropriateness
of different antidepressants in palliative care indicated
some convergence in opinion between round one and
two. In round two there was an even sharper distinc-
tion between those antidepressants deemed appropriate
in palliative care and those not (see Table 3). With the
exception of escitalopram, the favoured antidepressants
achieved an equal or higher median rating in round
two compared to round one, whereas the antidepres-
sants considered less appropriate, achieved an equal or
lower median rating in the second round. Thus, the
Delphi process contributed to a clearer picture of
experts’ opinion on choice of antidepressant. In rela-
tion to choice of screening tool and choice of psycho-
logical therapy, there was less evidence of convergence
in expert opinion between round one and two. How-
ever our aim was to evaluate experts’ views and assess
the level of expert agreement, not to achieve consensus
on clinical practice. The rang eo fr a t i n g si nt h i ss t u d y
reveals wide variation in expert opinion, which is
underscored by the contrasting comments clinicians
left to annotate their scores. Our sample of experts
was not sufficiently large to enable investigation of sys-
tematic differences in opinion based on characteristics
such as clinical specialty, country or age. This could be
a fruitful avenue for future research.
Conclusions
The Delphi method is an efficient and effective way of
eliciting expert opinion and promoting international col-
laboration. Experts with knowledge and experience of
managing depression in palliative care were unconvinced
about the benefits of screening and prefer to ‘ask’
patients about mood as part of routine symptom assess-
ment. Mirtazapine and citalopram were the considered
the best choice of antidepressant and cognitive beha-
vioural therapy the best choice of psychological therapy.
The range of expert ratings was broad, indicating discor-
dance in the views of experts. There was little evidence
of convergence of opinion in round two. The EPCRC
depression guideline aims to prevent inappropriate var-
iation in patient care by providing best practice recom-
mendations on managing depression in palliative care.
However, a paucity of high quality evidence precludes
definitive statements regarding the optimal screening
tool, antidepressant and psychological therapy. Direct
comparative data are needed to strengthen the evidence-
base and achieve clarity on how best to detect and treat
depression in this setting.
Additional material
Additional file 1: Delphi questionnaire. The questionnaire sent to the
Expert Group for the first round of the Delphi process.
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